ADMA Biologics Inc (ADMA)

Receivables turnover

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	US$ in thousands	426,454	258,215	154,080	80,943	42,220
Receivables	US$ in thousands	49,999	27,421	15,505	28,577	13,237
Receivables turnover		8.53	9.42	9.94	2.83	3.19

December 31, 2024 calculation

Receivables turnover = Revenue ÷ Receivables
= $426,454K ÷ $49,999K
= 8.53

The receivables turnover ratio for ADMA Biologics Inc has shown significant fluctuations over the past five years. In 2020, the ratio was 3.19, indicating that the company collected its accounts receivable approximately 3.19 times during that year. However, in 2021, the ratio decreased to 2.83, suggesting a slightly slower collection of receivables.

The years 2022, 2023, and 2024 witnessed a notable improvement in the receivables turnover ratio, with values of 9.94, 9.42, and 8.53, respectively. These higher ratios indicate that the company was more effective in collecting its accounts receivable during these years, possibly representing improved efficiency in managing its credit sales and collection processes.

Overall, the trend in ADMA Biologics Inc's receivables turnover ratios shows variability, with some years demonstrating stronger performance in accounts receivable collection than others. It is essential for the company to maintain a balance in managing its receivables to ensure a healthy cash flow and sustainable operations.